Trial Profile
Reversibility of Olfactory Loss in Patients With Idiopathic Parkinson's Disease Following Treatment With Rasagiline.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 04 Nov 2013 Results published in the Movement Disorders.
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
- 06 Feb 2012 Actual patient number is 34 according to ClinicalTrials.gov.